How LCA Treatments Work
Five families of therapy are racing to treat Leber Congenital Amaurosis — from a one-time gene fix to bionic and cell-replacement approaches. Scroll through each to see, step by step, how it works and where it fits.
Where in the eye do these work?
Light passes through the inner retina to reach the photoreceptors, which sit on a support layer called the retinal pigment epithelium (RPE). Most LCA therapies act on the photoreceptors or the RPE. When those cells are lost, optogenetics and implants instead target the surviving inner retina.
Inner retina
Bipolar & ganglion cells
Photoreceptors
Rods & cones
RPE
Support layer
Gene therapy, editing & RNA act here
Optogenetics & implants act here
Gene Augmentation Therapy
Deliver a healthy spare copy of the faulty gene
The most established approach. A harmless virus carries a working copy of the gene into retinal cells, which then make the protein the patient was missing — without altering the original mutation.
Step 1 / 5
Package the gene
Tap a step or the arrows to explore
Strengths
- One-time treatment with a long-lasting effect
- Clinically proven — the basis of FDA-approved Luxturna
- Targeted delivery limits effects elsewhere in the body
Limitations
- Only works for recessive, loss-of-function genes
- Large genes such as CEP290 do not fit inside an AAV
- Requires surviving photoreceptors — it cannot revive dead cells
One-time injection · durable
Luxturna (RPE65), ATSN-101 (GUCY2D), AIPL1 gene therapy, OPGx-LCA5 (LCA5)
Gene Editing (CRISPR)
Rewrite the mutation directly in the DNA
Instead of adding a spare gene, CRISPR tools find the exact mutation and edit the DNA in place — a permanent correction. Especially useful when the gene is too large to replace.
Step 1 / 5
Deliver the molecular scissors
Tap a step or the arrows to explore
Strengths
- Permanent correction at the DNA level
- Solves the problem of genes too big for AAV, such as CEP290
- A single, one-time treatment
Limitations
- Tailored to one specific mutation — not one-size-fits-all
- Edits are irreversible; off-target risk must be managed
- Still requires living photoreceptors
One-time · permanent DNA edit
EDIT-101 / BRILLIANCE trial (CEP290, LCA10) — the first in-body CRISPR therapy ever given to humans
RNA Therapy (Antisense)
Correct the message without touching the DNA
Short synthetic molecules tune how a gene's RNA message is read, restoring normal protein. Reversible and surgery-free — but the effect fades, so it must be repeated.
Step 1 / 5
An in-office injection
Tap a step or the arrows to explore
Strengths
- No surgery — a simple in-office injection into the eye
- Reversible and adjustable
- Early human trials showed real, measurable vision gains
Limitations
- Not permanent — needs lifelong repeat injections
- Matched to one specific mutation
- The pivotal sepofarsen trial missed its main goal
Repeat dosing · temporary
Sepofarsen (QR-110) for CEP290 (LCA10)
Stem Cell Therapy
Replace the cells the disease has already destroyed
When photoreceptors are gone, no gene therapy can help — there are no living cells left to fix. Stem-cell approaches aim to grow and transplant fresh retinal cells to rebuild the lost layer.
Step 1 / 5
Grow stem cells
Tap a step or the arrows to explore
Strengths
- The only approach aimed at cells that are already dead
- Potentially works regardless of which gene is mutated
- Patient-derived cells can lower the risk of rejection
Limitations
- For LCA this is still preclinical — no human LCA trial yet
- Getting new cells to survive and wire in correctly is unsolved
- Complex manufacturing and open safety questions
Intended one-time · investigational
Preclinical for LCA; hESC-derived RPE transplants have been tested in Stargardt and AMD
Optogenetics
Make surviving cells light-sensitive — for any gene
A gene-agnostic option for advanced vision loss: deliver a light-sensing protein to the retina's surviving inner neurons so they can take over for dead photoreceptors.
Step 1 / 5
Deliver a light-sensor gene
Tap a step or the arrows to explore
Strengths
- Works regardless of which LCA gene is mutated
- Doesn't need surviving photoreceptors
- A single gene delivery, used together with goggles
Limitations
- Restores only partial, low-resolution vision
- No LCA-specific trial yet — tested so far in retinitis pigmentosa
- Requires wearable goggles to work
One-time gene delivery · plus goggles
GS030 (ChrimsonR) — partial vision restored in a blind retinitis pigmentosa patient (Nature Medicine, 2021)
A closer look at one LCA type — to see how a single modality maps onto a specific gene and mechanism.
LCA1 — GUCY2D Gene Therapy
Restarting the photoreceptor's reset switch
LCA1 is caused by mutations in GUCY2D, the gene for the enzyme retGC1 that resets photoreceptors after each flash of light. In LCA1 the photoreceptors are often structurally well preserved, which makes it a strong candidate for gene augmentation — delivering a working GUCY2D copy by AAV.
Step 1 / 5
The reset switch is broken
Tap a step or the arrows to explore
Strengths
- Photoreceptors stay structurally intact in LCA1 — a wide treatment window
- Uses the same proven AAV augmentation approach as Luxturna
- ATSN-101 showed durable, dose-dependent vision gains (Lancet 2024)
Limitations
- Still requires the photoreceptors to be alive
- Specific to the GUCY2D / LCA1 genotype
- Not yet an approved therapy — still in clinical trials
One-time subretinal injection
ATSN-101 (Atsena Therapeutics) — AAV5-GUCY2D, Phase 1/2 (NCT03920007)
Two more approaches
Older or supportive strategies that shaped the field but are not first-line gene therapies today.
Oral retinoid (chromophore replacement)
Stalled after Phase 1bA daily pill supplies a synthetic version of the light-sensitive molecule the visual cycle cannot make in RPE65 or LRAT deficiency. Early trials showed rapid but temporary improvement; development has since stalled.
Retinal prosthesis (bionic eye)
DiscontinuedAn implanted electrode chip plus camera glasses electrically stimulate surviving retinal cells to create spots of light. The best-known device, Argus II, has been discontinued and is no longer supported.
Compare the approaches
Each therapy makes different trade-offs. Here is how the five gene- and cell-based approaches line up.
- What it changes
- Adds a spare gene
- Mutation-specific?
- Gene-specific
- Needs living photoreceptors?
- Yes
- Dosing
- One-time
- LCA maturity
- Approved (RPE65)
- What it changes
- Edits the DNA
- Mutation-specific?
- Mutation-specific
- Needs living photoreceptors?
- Yes
- Dosing
- One-time
- LCA maturity
- Proof of concept
- What it changes
- Tunes the RNA
- Mutation-specific?
- Mutation-specific
- Needs living photoreceptors?
- Yes
- Dosing
- Repeat
- LCA maturity
- Trial missed goal
- What it changes
- Replaces cells
- Mutation-specific?
- Gene-agnostic
- Needs living photoreceptors?
- No
- Dosing
- One-time
- LCA maturity
- Preclinical
- What it changes
- Adds a light sensor
- Mutation-specific?
- Gene-agnostic
- Needs living photoreceptors?
- No
- Dosing
- One-time + goggles
- LCA maturity
- RP only so far
Matching therapy to disease stage
The biggest factor is how much retina remains. While photoreceptors are alive, gene-based fixes can preserve and restore them. Once those cells are lost, only cell-replacement or light-sensor approaches remain.
Photoreceptors still alive
Gene augmentation · Gene editing · RNA therapy
Photoreceptors lost
Stem cell · Optogenetics · Retinal implant
This is a simplified guide, not medical advice — eligibility depends on genotype, age and retinal imaging.
This page explains how treatment approaches work in general terms. It is not medical advice, and clinical-trial status changes frequently — always confirm options and eligibility with your medical team.
Explore the specific treatments
See the approved therapy and the full trial pipeline for each LCA gene.